HeartPoint Global inc. is a medical device technology company dedicated to improving lives globally by providing disruptive, safer, cost-effective, accessible, and minimally invasive treatments for numerous cardiovascular indications that annually affect tens of millions of people worldwide. HeartPoint Global's patented device and system, the HeartPoint Global Interventional System (HPGIS), is a first of its kind system of stents that allows for the adjustment of blood flow, at any time during or after initial insertion, in the main pulmonary artery and/or its branches to restore the structure of the heart and function of the heart-lung system, addressing numerous cardiovascular diseases. Initially focusing on left heart issues and structural pulmonary hypertension (for which there is currently no effective treatment) The HPGIS is an investigational device, imminently to be evaluated in clinical trials in Europe.
Heartpoint Global Israel Ltd is the company local R&D subsidiary.